Why Xencor, Inc.’s (XNCR) Stock Is Down 5.21%
As of Friday, July 31, Xencor, Inc.’s XNCR share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn’s disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Commentary & Analysis
Why Xencor, Inc.’s (XNCR) Stock Is Up 6.30%
As of Thursday, July 30, Xencor, Inc.’s XNCR share price has surged by 6.30%, which has investors questioning if this is right time to sell.Michael Rose
Why Xencor, Inc.’s (XNCR) Stock Is Up 9.62%
As of Tuesday, July 21, Xencor, Inc.’s XNCR share price has surged by 9.62%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Xencor, Inc.’s (XNCR) Stock Is Up 13.28%
As of Monday, July 20, Xencor, Inc.’s XNCR share price has surged by 13.28%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Xencor, Inc.’s (XNCR) Stock Is Up 10.59%
As of Monday, July 20, Xencor, Inc.’s XNCR share price has surged by 10.59%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | XNCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,593.3 | $251.9 | 51% |
|
| Shares Out (Mil) | 75.2 | 50.8 | 57% |
|
| Institutional Ownership | 98.7% | 92.0% | 81% |
|
| Float (Mil) | 54.4 | 40.5 | 49% |
|
| Beta | 0.93 | 0.95 | 55% |
|
| Avg Daily Volume (000s) | 1,366 | 447 | 76% |
|
| Price Change (52-week) |
143.7% | 54.2% | 95% |
|
| Growth | XNCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.5% | 14.0% | 18% |
|
| Net Income (5yr) | (5.8%) | (9.8%) | 33% |
|
| EPS (5yr) | (0.4%) | 16.3% | 30 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (38.1%) | (15.6%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 12 | 12 | |
| Current EPS | ($0.842) | ($4.026) | ($3.548) | |
| Month Ago EPS | ($0.832) | ($3.994) | ($3.559) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.761) | ($3.078) | ($3.042) | |
| Year/Year Chg | (50.8%) | 225.2% | 157.2% | |
| Financials | XNCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $97 | $39 | 26% |
|
| Net Income (TTM) (Mil) | ($172) | ($43) | 7% |
|
| EPS (TTM) | ($2.310) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($187) | ($30) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($26) | $3 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $145 | $5 | 47% |
|
| Enterprise Value (Q1) (Mil) | $486 | $182 | 34% |
|
| Valuation | XNCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.09 | 2.60 | 66% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | XNCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (152.2%) | 63.8% | 1% |
|
| Net Margin | (177.1%) | (64.7%) | 5% |
|
| ROA | (21.0%) | (49.7%) | 20% |
|
| ROE | (29.8%) | (55.4%) | 20% |
|
| Liabilities to Assets | 30.0% | 30.3% | 21% |
|
| F-Score | 3 | 3 | 19% |
|
Xencor, Inc. did not pass any screens on 7/30/2026.
